Lucid Diagnostics’ EsoGuard esophageal precancer testing shows efficacy

Lucid Diagnostics (LUCD), a subsidiary of PAVmed (PAVM), announced the release of new real-world data from its ENVET-BE study supporting the clinical utility of the EsoGuard Esophageal DNA test as a non-invasive triage tool to significantly increase the positive yield of invasive upper endoscopy – EGD -. for detection of esophageal precancer and cancer. Patients triaged to invasive EGD following a positive non-invasive EsoGuard test had a 2.4-fold increase in the positive yield of those EGDs compared to the expected yield of screening EGD alone in at-risk patients. EGD confirmed a BE diagnosis in 50 of the 199 patients in a real-world commercial setting who underwent clinically directed EsoGuard testing and received a positive EsoGuard result. This represents a post-triage EGD yield of 25%, a 2.4-fold increase over the expected 11% yield of EGD as a standalone screening tool in the at-risk population. These findings are consistent with those previously published in the American Journal of Gastroenterology for a study conducted at the Cleveland VA that utilized EsoGuard for screening high-risk veterans.